Immutep stock jumps 11% on positive data for eftilagimod alpha (NASDAQ:IMMP)

Shares of Immutep (NASDAQ:IMMP) climbed 11% Thursday after the Australian company reported positive data from two clinical trials of its drug candidate eftilagimod alpha, or efti.

Immutep (IMMP) said a Phase 2 study of efti in combination with radiotherapy